Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samir Parekh

Showing results (71-80 of 162) with videos related to

Pageof 17
Sort By:
Blood Advances|November 15, 2024
MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myelomaLucia Y Chen, Santiago Thibaud, Saoirse Bodnar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2012
Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphomaAdam M Petrich, Violetta Leshchenko, Pei-Yu Kuo, et al.
Science Translational Medicine|June 26, 2015
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemiaZainul S Hasanali, Bikramajit Singh Saroya, August Stuart, et al.
Blood|June 5, 2007
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanismsSamir Parekh, Jose M Polo, Rita Shaknovich, et al.
Blood|July 21, 2011
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCLMatko Kalac, Luigi Scotto, Enrica Marchi, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 13, 2023
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual WorkshopEvangelos Terpos, Paola Neri, Niels W C J van de Donk, et al.
Haematologica|April 23, 2026
Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumabGuido Lancman, Dahniel Sastow, Minira Aslanova, et al.
Blood|April 5, 2018
SOX11 augments BCR signaling to drive MCL-like tumor developmentPei-Yu Kuo, Shashidhar S Jatiani, Adeeb H Rahman, et al.
Journal for Immunotherapy of Cancer|April 12, 2024
Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myelomaDavid G Coffey, Keren Osman, Adolfo Aleman, et al.
Journal of Hematology & Oncology|May 9, 2023
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutationMuhammad Elnaggar, Sarita Agte, Paula Restrepo, et al.
Pageof 17

Showing results (71-80 of 162) with videos related to

Sort By:
Pageof 17
Blood Advances|November 15, 2024
MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myelomaLucia Y Chen, Santiago Thibaud, Saoirse Bodnar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2012
Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphomaAdam M Petrich, Violetta Leshchenko, Pei-Yu Kuo, et al.
Science Translational Medicine|June 26, 2015
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemiaZainul S Hasanali, Bikramajit Singh Saroya, August Stuart, et al.
Blood|June 5, 2007
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanismsSamir Parekh, Jose M Polo, Rita Shaknovich, et al.
Blood|July 21, 2011
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCLMatko Kalac, Luigi Scotto, Enrica Marchi, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 13, 2023
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual WorkshopEvangelos Terpos, Paola Neri, Niels W C J van de Donk, et al.
Haematologica|April 23, 2026
Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumabGuido Lancman, Dahniel Sastow, Minira Aslanova, et al.
Blood|April 5, 2018
SOX11 augments BCR signaling to drive MCL-like tumor developmentPei-Yu Kuo, Shashidhar S Jatiani, Adeeb H Rahman, et al.
Journal for Immunotherapy of Cancer|April 12, 2024
Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myelomaDavid G Coffey, Keren Osman, Adolfo Aleman, et al.
Journal of Hematology & Oncology|May 9, 2023
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutationMuhammad Elnaggar, Sarita Agte, Paula Restrepo, et al.
Pageof 17